



Combining to create an innovative global musculoskeletal company

February 9, 2023



Legal disclaimers

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Cautionary Notes on Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining shareholder and regulatory approvals, (iii) the anticipated tax treatment of the transaction may not be obtained, (iv) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business after the consummation of the transactions, (v) potential litigation relating to the proposed transaction that could be instituted against Globus Medical, NuVasive or their respective directors, (vi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transactions, (vii) any negative effects of the announcement, pendency or consummation of the transactions on the market price of Globus Medical’s or NuVasive’s common stock and on Globus Medical’s or NuVasive’s operating results, (viii) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (ix) the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, the businesses successfully and to achieve anticipated synergies, (x) the risk that disruptions from the proposed transaction will harm Globus Medical’s or NuVasive’s business, including current plans and operations, (xi) the ability of Globus Medical or NuVasive to retain and hire key personnel and uncertainties arising from leadership changes, (xii) legislative, regulatory and economic developments, and (xiii) the other risks described in Globus Medical’s and NuVasive’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q.

These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the joint proxy statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Globus Medical’s or NuVasive’s consolidated financial condition, results of operations, credit rating or liquidity. Neither Globus Medical nor NuVasive assumes any obligation to publicly provide revisions or updates to any forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Legal disclaimers

Important Information About the Transaction and Where To Find It

In connection with the proposed transaction, Globus Medical will file with the U.S. Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 that will include a joint proxy statement of Globus Medical and NuVasive and that will also constitute a prospectus of Globus Medical for shares of its class A common stock to be offered in the proposed transaction. Globus Medical and NuVasive may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the joint proxy statement statement/prospectus or registration statement or any other document which Globus Medical or NuVasive may file with the SEC. INVESTORS AND SECURITY HOLDERS OF GLOBUS MEDICAL AND NUVASIVE ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH WILL INCLUDE THE JOINT PROXY STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement, definitive joint proxy statement/prospectus and other documents filed by Globus Medical and NuVasive with the SEC will be available free of charge at the SEC’s website (www.sec.gov) and from Globus Medical and NuVasive. Requests for copies of the joint proxy statement/prospectus and other documents filed by Globus Medical with the SEC may be made by contacting Keith Pfeil, Chief Financial Officer by phone at (610) 930-1800 or by email at kpfeil@globusmedical.com, and request for copies of the joint proxy statement/prospectus and other documents filed by NuVasive may be made by contacting Matt Harbaugh, Chief Financial Officer, by phone at (858) 210-2129 or by email at investorrelations@nuvasive.com.

Participants in the Solicitation

Globus Medical, NuVasive, their respective directors and certain of their executive officers and other employees may be deemed to be participants in the solicitation of proxies from Globus Medical’s and NuVasive’s shareholders in connection with the proposed transaction. Information about the directors and executive officers of Globus Medical and their ownership of Globus Medical stock is set forth in Globus Medical’s annual report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 17, 2022 and its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on April 21, 2022. Information regarding NuVasive’s directors and executive officers is contained in NuVasive’s annual report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 23, 2022, and its proxy statement for its 2022 annual meeting of stockholders, which was filed with the SEC on March 30, 2022. Certain directors and executive officers of Globus Medical and NuVasive may have a direct or indirect interest in the transaction due to securities holdings, vesting of equity awards and rights to severance payments. Additional information regarding the persons who, may under the rules of the SEC, be deemed participants in the solicitation of Globus Medical’s and NuVasive’s shareholders in connection with the proposed transaction will be included in the joint proxy statement/prospectus. These documents can be obtained free of charge from the sources indicated above.

Non-GAAP Measures

This communication includes certain non-GAAP measures not based on generally accepting accounting principles. These non-GAAP measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP measures used by Globus Medical and/or NuVasive may differ from the non-GAAP measured used by other companies.

Focused on superior outcomes in patient care

Relentless pursuit of unmet clinical needs because today's outcomes still need to evolve further to advance musculoskeletal care



Value creation for key stakeholders



PATIENTS

- Continued focus on improving patient outcomes
- Access to best-in-class product portfolio
- Combined resources for future innovation to solve unmet clinical needs



SURGEONS

- Expands product offerings in procedures and enabling technologies
- Leverages talent from both organizations
- Enhanced sales distribution networks
- Commitment to global surgeon education and research



EMPLOYEES

- Shared commitment to patient-focused innovation
- Strong sense of urgency
- Opportunities for career advancement
- Integrates infrastructure and resources
- Passionate workforce



SHAREHOLDERS

- Expected to be accretive to adjusted non-GAAP EPS within year 1 post-close
- Financial discipline anticipated to drive EBITDA to mid-30s by year 3
- ROIC expected to exceed the cost of capital by year 3

Combination creates innovative, global musculoskeletal company



Complementary global footprint to support more patients and surgeons



Comprehensive and innovative portfolio in spine and orthopedics



Continued commitment to product development and surgeon education



Expands operational capabilities



Compelling upside revenue potential



Strong financial profile and value creation opportunity for shareholders



Transaction overview

Structure

- **Stock-for-stock merger**
- **NuVasive shareholders will receive a fixed exchange ratio of 0.75 Globus Medical share for each NuVasive share**

Anticipated Post-Closing Ownership

- **Globus Medical shareholders: 72%**
- **NuVasive shareholders: 28%**

Governance

- **Executive Chairman:** David Paul
- **Chief Executive Officer:** Dan Scavilla
- **Chief Financial Officer:** Keith Pfeil
- **Chris Barry** to support integration planning efforts
- **Board:** To consist of all eight Globus Medical board members and three members from the NuVasive board

Name / Ticker


- **Name:** Combined company name to be announced at or prior to closure
- **Ticker:** GMED
- **Primary corporate office:** Audubon, PA/ **Other offices** (*including but not limited to*): San Diego, CA and Methuen, MA

Conditions / Timing

- **Globus Medical and NuVasive shareholder approvals**
- **Regulatory approvals and other closing conditions**
- **Expected closing:** Middle of 2023


A shared history of innovation and growth

Annual Sales (\$M)



Market

\$50B total addressable market with multiple high-growth levers





Complementary U.S. commercial organizations



Accelerates globalization strategies to target and win in high-growth markets



A combined presence in more than 50 countries




Complementary international footprint in key markets

Australia/New Zealand, Brazil, Germany, Italy, Japan, U.K.



Creates immediate scale globally and ability to effectively invest in high-growth markets



Comprehensive portfolio of spine solutions to help improve patient care

Excelsius3D®
Imaging system



Pulse platform



ExcelsiusGPS®
Robotic System



NuVasive
Clinical Services



Globus Medical

NuVasive

NuVasive
ACP system



MAGEC
system



HEDRON®
Interbody
Fusion



CREO MIS®
Fixation System



XLIF



Simplify
cervical disc



Quartex®
Fixation System



FORTIFY®
Corpectomy
System



SABLE®
Interbody
Fusion



Reline
system



RISE-L®
Interbody
Fusion



Modulus
ALIF



Comprehensive portfolio of orthopedic solutions to help improve patient care

Excelsius3D®
Imaging
system




ExcelsiusHub
Navigation
System



Globus Medical

NuVasive



Positioned to address the continuum of patient care with intelligent surgery

Pre-op

Intra-op

Post-op

Patient assessment & optimization



Procedure selection & planning



Procedure execution & verification



Healing & recovery monitoring



Outcome evaluation & continual learning



Continued commitment to surgeon education and research



Surgeon trainings

2,500+ surgeons trained in 2022*



Clinical studies, research

More than 800 peer reviewed publications and 70+ ongoing clinical studies*




SpineTRACK registry

Prospective, multicenter, observational data collection quality improvement tool established in 2011



Longstanding, society and research partnerships

Support industry's leading study groups to help advance care



Expands operational expertise

Focus on unlocking manufacturing capacity and increasing asset utilization to improve customer service level

Leverage NuVasive's
~100,000-square foot
Memphis, TN

global distribution center



Increase utilization of NuVasive's
~180,000-square foot
West Carrollton, OH

manufacturing plant



Expertise from Globus Medical's
>300,000 square foot manufacturing plants in
Limerick, PA, Audubon, PA & San Antonio, TX

**to manufacture
+80% implants in-house**



Employees

- Shared commitment to patient-focused innovation
- Strong sense of urgency
- Opportunities for career advancement
- Integrates infrastructure and resources
- Passionate workforce

Combination creates a compelling financial profile for shareholders



Anticipate above market mid- to high-single digit growth



Expected to achieve mid-30s EBITDA* margins by year three



~\$170M in cost synergies expected to be achieved by year three



Accretive to Non-GAAP EPS* anticipated in the first year post-close



ROIC* expected to exceed the cost of capital by year 3



Our vision

Diversified, leading musculoskeletal technology company



Thought and industry leadership in spine



Innovation in imaging, navigation, and robotics



Build strong foundation in trauma and total joint arthroplasty



Continue to expand in other musculoskeletal areas, including regenerative biologics, sports medicine, power tools and extremities



Combining to create an innovative, global musculoskeletal company focused on patient care

